Koninklijke DSM N.V.

As of December 31, 2020, Koninklijke DSM N.V. has 172.22M shares outstanding.

As of December 31, 2020, Koninklijke DSM N.V. trades at a trailing price-to-earnings ratio of 44.44. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 2.92.

As of December 31, 2020, Koninklijke DSM N.V. trades at an EV/EBITDA multiple of 30.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 30.21 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Koninklijke DSM N.V. trades at an EV/FCF ratio of 17.53, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2020, Koninklijke DSM N.V. maintains a current ratio of 2.42, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2020, Koninklijke DSM N.V. posted a return on equity (ROE) of 6.60, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.60 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.84, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.69, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended December 31, 2020. That works out to an effective tax rate of 18.40, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2020, Koninklijke DSM N.V. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 10.23 and net profit margin of 6.23 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2020. The dividend payout ratio of 25.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.35, meaning Koninklijke DSM N.V. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Koninklijke DSM N.V.'s most recent stock split took place on October 14, 2005 with a 1:2 split ratio.

As of December 31, 2020, Koninklijke DSM N.V. has an Altman Z-Score of 4.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.